Last reviewed · How we verify
NCT03658044: SMOP
Social Media on Prescription for Colorectal Cancer Patients
NA trial testing Participation in the internet forum in Colorectal Cancer in 44 participants. Completed in 10 October 2021.
31 October 2020
Quick facts
| Lead sponsor | Sahlgrenska University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 44 |
| Start date | 1 December 2018 |
| Primary completion | 31 October 2020 |
| Estimated completion | 10 October 2021 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- Participation in the internet forum
- Placebo
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
Sponsor
Sahlgrenska University Hospital
Who can join
18 and older, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall aim with this study is to get a deeper understanding of the potential benefits with a health platform for patients diagnosed with colorectal cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Behavioural interventions delivered through interactive social media for health behaviour change, health outcomes, and health equity in the adult population.
Petkovic J, Duench S, Trawin J, Dewidar O, et al · · 2021 · cited 78× · PMID 34057201 · DOI 10.1002/14651858.cd012932.pub2
Verify or expand the search:
- PubMed search for NCT03658044
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Sahlgrenska University Hospital trials
Trials by the same sponsor.
- NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
- NCT07524608 — Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Pa · not yet recruiting
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT06896578 — Latitude - Lateral Lymph Node Attitude Study · NA · not yet recruiting
- NCT07035600 — Walking and Sitting Difficulties After Rectal Cancer Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03658044 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sahlgrenska University Hospital
- Last refreshed: 7 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03658044.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing